[{"path":"/LICENSE.html","id":null,"dir":"","previous_headings":"","what":"Apache License","title":"Apache License","text":"Version 2.0, January 2004 <http://www.apache.org/licenses/>","code":""},{"path":[]},{"path":"/LICENSE.html","id":"id_1-definitions","dir":"","previous_headings":"Terms and Conditions for use, reproduction, and distribution","what":"1. Definitions","title":"Apache License","text":"“License” shall mean terms conditions use, reproduction, distribution defined Sections 1 9 document. “Licensor” shall mean copyright owner entity authorized copyright owner granting License. “Legal Entity” shall mean union acting entity entities control, controlled , common control entity. purposes definition, “control” means () power, direct indirect, cause direction management entity, whether contract otherwise, (ii) ownership fifty percent (50%) outstanding shares, (iii) beneficial ownership entity. “” (“”) shall mean individual Legal Entity exercising permissions granted License. “Source” form shall mean preferred form making modifications, including limited software source code, documentation source, configuration files. “Object” form shall mean form resulting mechanical transformation translation Source form, including limited compiled object code, generated documentation, conversions media types. “Work” shall mean work authorship, whether Source Object form, made available License, indicated copyright notice included attached work (example provided Appendix ). “Derivative Works” shall mean work, whether Source Object form, based (derived ) Work editorial revisions, annotations, elaborations, modifications represent, whole, original work authorship. purposes License, Derivative Works shall include works remain separable , merely link (bind name) interfaces , Work Derivative Works thereof. “Contribution” shall mean work authorship, including original version Work modifications additions Work Derivative Works thereof, intentionally submitted Licensor inclusion Work copyright owner individual Legal Entity authorized submit behalf copyright owner. purposes definition, “submitted” means form electronic, verbal, written communication sent Licensor representatives, including limited communication electronic mailing lists, source code control systems, issue tracking systems managed , behalf , Licensor purpose discussing improving Work, excluding communication conspicuously marked otherwise designated writing copyright owner “Contribution”. “Contributor” shall mean Licensor individual Legal Entity behalf Contribution received Licensor subsequently incorporated within Work.","code":""},{"path":"/LICENSE.html","id":"id_2-grant-of-copyright-license","dir":"","previous_headings":"Terms and Conditions for use, reproduction, and distribution","what":"2. Grant of Copyright License","title":"Apache License","text":"Subject terms conditions License, Contributor hereby grants perpetual, worldwide, non-exclusive, -charge, royalty-free, irrevocable copyright license reproduce, prepare Derivative Works , publicly display, publicly perform, sublicense, distribute Work Derivative Works Source Object form.","code":""},{"path":"/LICENSE.html","id":"id_3-grant-of-patent-license","dir":"","previous_headings":"Terms and Conditions for use, reproduction, and distribution","what":"3. Grant of Patent License","title":"Apache License","text":"Subject terms conditions License, Contributor hereby grants perpetual, worldwide, non-exclusive, -charge, royalty-free, irrevocable (except stated section) patent license make, made, use, offer sell, sell, import, otherwise transfer Work, license applies patent claims licensable Contributor necessarily infringed Contribution(s) alone combination Contribution(s) Work Contribution(s) submitted. institute patent litigation entity (including cross-claim counterclaim lawsuit) alleging Work Contribution incorporated within Work constitutes direct contributory patent infringement, patent licenses granted License Work shall terminate date litigation filed.","code":""},{"path":"/LICENSE.html","id":"id_4-redistribution","dir":"","previous_headings":"Terms and Conditions for use, reproduction, and distribution","what":"4. Redistribution","title":"Apache License","text":"may reproduce distribute copies Work Derivative Works thereof medium, without modifications, Source Object form, provided meet following conditions: () must give recipients Work Derivative Works copy License; (b) must cause modified files carry prominent notices stating changed files; (c) must retain, Source form Derivative Works distribute, copyright, patent, trademark, attribution notices Source form Work, excluding notices pertain part Derivative Works; (d) Work includes “NOTICE” text file part distribution, Derivative Works distribute must include readable copy attribution notices contained within NOTICE file, excluding notices pertain part Derivative Works, least one following places: within NOTICE text file distributed part Derivative Works; within Source form documentation, provided along Derivative Works; , within display generated Derivative Works, wherever third-party notices normally appear. contents NOTICE file informational purposes modify License. may add attribution notices within Derivative Works distribute, alongside addendum NOTICE text Work, provided additional attribution notices construed modifying License. may add copyright statement modifications may provide additional different license terms conditions use, reproduction, distribution modifications, Derivative Works whole, provided use, reproduction, distribution Work otherwise complies conditions stated License.","code":""},{"path":"/LICENSE.html","id":"id_5-submission-of-contributions","dir":"","previous_headings":"Terms and Conditions for use, reproduction, and distribution","what":"5. Submission of Contributions","title":"Apache License","text":"Unless explicitly state otherwise, Contribution intentionally submitted inclusion Work Licensor shall terms conditions License, without additional terms conditions. Notwithstanding , nothing herein shall supersede modify terms separate license agreement may executed Licensor regarding Contributions.","code":""},{"path":"/LICENSE.html","id":"id_6-trademarks","dir":"","previous_headings":"Terms and Conditions for use, reproduction, and distribution","what":"6. Trademarks","title":"Apache License","text":"License grant permission use trade names, trademarks, service marks, product names Licensor, except required reasonable customary use describing origin Work reproducing content NOTICE file.","code":""},{"path":"/LICENSE.html","id":"id_7-disclaimer-of-warranty","dir":"","previous_headings":"Terms and Conditions for use, reproduction, and distribution","what":"7. Disclaimer of Warranty","title":"Apache License","text":"Unless required applicable law agreed writing, Licensor provides Work (Contributor provides Contributions) “” BASIS, WITHOUT WARRANTIES CONDITIONS KIND, either express implied, including, without limitation, warranties conditions TITLE, NON-INFRINGEMENT, MERCHANTABILITY, FITNESS PARTICULAR PURPOSE. solely responsible determining appropriateness using redistributing Work assume risks associated exercise permissions License.","code":""},{"path":"/LICENSE.html","id":"id_8-limitation-of-liability","dir":"","previous_headings":"Terms and Conditions for use, reproduction, and distribution","what":"8. Limitation of Liability","title":"Apache License","text":"event legal theory, whether tort (including negligence), contract, otherwise, unless required applicable law (deliberate grossly negligent acts) agreed writing, shall Contributor liable damages, including direct, indirect, special, incidental, consequential damages character arising result License use inability use Work (including limited damages loss goodwill, work stoppage, computer failure malfunction, commercial damages losses), even Contributor advised possibility damages.","code":""},{"path":"/LICENSE.html","id":"id_9-accepting-warranty-or-additional-liability","dir":"","previous_headings":"Terms and Conditions for use, reproduction, and distribution","what":"9. Accepting Warranty or Additional Liability","title":"Apache License","text":"redistributing Work Derivative Works thereof, may choose offer, charge fee , acceptance support, warranty, indemnity, liability obligations /rights consistent License. However, accepting obligations, may act behalf sole responsibility, behalf Contributor, agree indemnify, defend, hold Contributor harmless liability incurred , claims asserted , Contributor reason accepting warranty additional liability. END TERMS CONDITIONS","code":""},{"path":"/LICENSE.html","id":"appendix-how-to-apply-the-apache-license-to-your-work","dir":"","previous_headings":"","what":"APPENDIX: How to apply the Apache License to your work","title":"Apache License","text":"apply Apache License work, attach following boilerplate notice, fields enclosed brackets [] replaced identifying information. (Don’t include brackets!) text enclosed appropriate comment syntax file format. also recommend file class name description purpose included “printed page” copyright notice easier identification within third-party archives.","code":"Copyright 2025 F. Hoffmann-La Roche AG and GlaxoSmithKline LLC and J&J Innovative Medicine  Licensed under the Apache License, Version 2.0 (the \"License\"); you may not use this file except in compliance with the License. You may obtain a copy of the License at    http://www.apache.org/licenses/LICENSE-2.0  Unless required by applicable law or agreed to in writing, software distributed under the License is distributed on an \"AS IS\" BASIS, WITHOUT WARRANTIES OR CONDITIONS OF ANY KIND, either express or implied. See the License for the specific language governing permissions and limitations under the License."},{"path":"/authors.html","id":null,"dir":"","previous_headings":"","what":"Authors","title":"Authors and Citation","text":"David Munoz Tord. Author, maintainer. Nicholas Masel. Author. Joe Kovach. Author. Mahesh Divakaran. Contributor. J&J Innovative Medicine. Copyright holder, funder.","code":""},{"path":"/authors.html","id":"citation","dir":"","previous_headings":"","what":"Citation","title":"Authors and Citation","text":"Munoz Tord D, Masel N, Kovach J (2025). pharmaverseadamjnj: J&J Innovative Medicine ADaM Test Data. R package version 0.0.1.","code":"@Manual{,   title = {pharmaverseadamjnj: J&J Innovative Medicine ADaM Test Data},   author = {David {Munoz Tord} and Nicholas Masel and Joe Kovach},   year = {2025},   note = {R package version 0.0.1}, }"},{"path":"/index.html","id":"pharmaverseadamjnj","dir":"","previous_headings":"","what":"J&J Innovative Medicine ADaM Test Data","title":"J&J Innovative Medicine ADaM Test Data","text":"Generate ADaM datasets aligned Johnson & Johnson’s Clinical Statistical Programming standards.","code":""},{"path":"/index.html","id":"features","dir":"","previous_headings":"","what":"Features","title":"J&J Innovative Medicine ADaM Test Data","text":"Generates ADaM datasets comply J&J standards Built top pharmaverseadam package Implements data conversion pharmaverse format J&J standards format Provides reproducible consistent test data","code":""},{"path":"/index.html","id":"implemented-datasets","dir":"","previous_headings":"","what":"Implemented Datasets","title":"J&J Innovative Medicine ADaM Test Data","text":"Currently supports following ADaM domains: ADSL (Subject Level Analysis Dataset) ADAE (Adverse Events Analysis Dataset) ADCM (Concomitant Medications Analysis Dataset) ADEG (ECG Analysis Dataset) ADEX (Exposure Analysis Dataset) ADESUM (Exposure Analysis Summary Dataset) ADLB (Laboratory Test Results Analysis Dataset) ADVS (Vital Signs Analysis Dataset) ADTTESAF (Time--Event Safety Analysis Dataset) ADAEFMQ (Adverse Events Analysis Dataset FDA Medical Query)","code":""},{"path":"/index.html","id":"installation","dir":"","previous_headings":"","what":"Installation","title":"J&J Innovative Medicine ADaM Test Data","text":"can install development version GitHub:","code":"# install.packages(\"devtools\") devtools::install_github(\"johnsonandjohnson/pharmaverseadamjnj\")"},{"path":"/index.html","id":"usage","dir":"","previous_headings":"","what":"Usage","title":"J&J Innovative Medicine ADaM Test Data","text":"","code":"library(pharmaverseadamjnj)  # Access the ADaM datasets directly # These datasets are loaded lazily when the package is loaded head(adsl) head(adae) head(adlb) # ... and similarly for other domains"},{"path":"/index.html","id":"data-sources","dir":"","previous_headings":"","what":"Data Sources","title":"J&J Innovative Medicine ADaM Test Data","text":"Test datasets sourced pharmaverseadam package, utilized data pharmaversesdtm package CDISC pilot project.","code":""},{"path":"/reference/adae.html","id":null,"dir":"Reference","previous_headings":"","what":"adae — adae","title":"adae — adae","text":"adae modified pharmaverseadam","code":""},{"path":"/reference/adae.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"adae — adae","text":"","code":"adae"},{"path":"/reference/adae.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"adae — adae","text":"data frame 1191 rows 80 variables: DOMAIN Domain Abbreviation USUBJID Unique Subject Identifier AESEQ Sequence Number AESPID Sponsor-Defined Identifier AETERM Reported Term Adverse Event AELLT Lowest Level Term AELLTCD Lowest Level Term Code AEDECOD Dictionary-Derived Term AEPTCD Preferred Term Code AEHLT High Level Term AEHLTCD High Level Term Code AEHLGT High Level Group Term AEHLGTCD High Level Group Term Code AEBODSYS Body System Organ Class AEBDSYCD Body System Organ Class Code AESOC Primary System Organ Class AESOCCD Primary System Organ Class Code AESEV Severity/Intensity AESER Serious Event AEACN Action Taken Study Treatment AEREL Causality AEOUT Outcome Adverse Event AESCAN Involves Cancer AESCONG Congenital Anomaly Birth Defect AESDISAB Persist Signif Disability/Incapacity AESDTH Results Death AESHOSP Requires Prolongs Hospitalization AESLIFE Life Threatening AESOD Occurred Overdose AEDTC Date/Time Collection AESTDTC Start Date/Time Adverse Event AEENDTC End Date/Time Adverse Event AESTDY Study Day Start Adverse Event AEENDY Study Day End Adverse Event ASTDTM Analysis Start Date/Time ASTDTF Analysis Start Date Imputation Flag ASTTMF Analysis Start Time Imputation Flag AENDTM Analysis End Date/Time AENDTF Analysis End Date Imputation Flag AENTMF Analysis End Time Imputation Flag ASTDT Analysis Start Date AENDT Analysis End Date ASTDY Analysis Start Relative Day AENDY Analysis End Relative Day ADURN Analysis Duration (N) ADURU Analysis Duration Units LDOSEDTM End Date/Time Last Dose ASEV Analysis Severity/Intensity AREL Analysis Causality TRTEMFL Treatment Emergent Analysis Flag ASEVN Analysis Severity/Intensity (N) AOCCIFL 1st Max Sev./Int. Occurrence Flag AETOXGR Standard Toxicity Grade AETOXGRN Standard Toxicity Grade (N) AEACN_DECODE Action Taken Study Treatment DOSEDY Day Study Drug DOSEU Treatment Dose Units DOSEON Treatment Dose Record Start AECONTRT Concomitant Additional Trtmnt Given CQ01NAM Customized Query 01 Name CQ02NAM Customized Query 02 Name CQ03NAM Customized Query 03 Name AESMIE Medically Important Serious Event AESER_DECODE Serious Event AEREL_DECODE Causality AEOUT_DECODE Outcome Adverse Event AOCCFL 1st Occurence within Subject Flag AOCCPFL 1st Occurence within Preferred Term Flag AOCCSFL 1st Occurrence SOC Flag TRT01A Actual Treatment Period 01 SAFFL Safety Population Flag AGE Age SEX Sex RACE Race RACE_DECODE Race STUDYID Study Identifier AGEGR1 Pooled Age Group 1 TRTEDY Treatment Relative End Day TRT01P Planned Treatment Period 01 ACAT1 Analysis Category 1","code":""},{"path":"/reference/adae.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"adae — adae","text":"data pharmaverseadam.","code":""},{"path":[]},{"path":"/reference/adae.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"adae — adae","text":"","code":"if (FALSE) { # \\dontrun{ data(\"adae\") } # }"},{"path":"/reference/adaefmq.html","id":null,"dir":"Reference","previous_headings":"","what":"adaefmq — adaefmq","title":"adaefmq — adaefmq","text":"adae modified pharmaverseadam include FDA Medical Query information","code":""},{"path":"/reference/adaefmq.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"adaefmq — adaefmq","text":"","code":"adaefmq"},{"path":"/reference/adaefmq.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"adaefmq — adaefmq","text":"data frame 1979 rows 83 variables: DOMAIN Domain Abbreviation USUBJID Unique Subject Identifier AESEQ Sequence Number AESPID Sponsor-Defined Identifier AETERM Reported Term Adverse Event AELLT Lowest Level Term AELLTCD Lowest Level Term Code AEDECOD AEDECOD AEPTCD Preferred Term Code AEHLT High Level Term AEHLTCD High Level Term Code AEHLGT High Level Group Term AEHLGTCD High Level Group Term Code AEBODSYS Body System Organ Class AEBDSYCD Body System Organ Class Code AESOC Primary System Organ Class AESOCCD Primary System Organ Class Code AESEV Severity/Intensity AESER Serious Event AEACN Action Taken Study Treatment AEREL Causality AEOUT Outcome Adverse Event AESCAN Involves Cancer AESCONG Congenital Anomaly Birth Defect AESDISAB Persist Signif Disability/Incapacity AESDTH Results Death AESHOSP Requires Prolongs Hospitalization AESLIFE Life Threatening AESOD Occurred Overdose AEDTC Date/Time Collection AESTDTC Start Date/Time Adverse Event AEENDTC End Date/Time Adverse Event AESTDY Study Day Start Adverse Event AEENDY Study Day End Adverse Event ASTDTM Analysis Start Date/Time ASTDTF Analysis Start Date Imputation Flag ASTTMF Analysis Start Time Imputation Flag AENDTM Analysis End Date/Time AENDTF Analysis End Date Imputation Flag AENTMF Analysis End Time Imputation Flag ASTDT Analysis Start Date AENDT Analysis End Date ASTDY Analysis Start Relative Day AENDY Analysis End Relative Day ADURN Analysis Duration (N) ADURU Analysis Duration Units LDOSEDTM End Date/Time Last Dose ASEV Analysis Severity/Intensity AREL Analysis Causality TRTEMFL Treatment Emergent Analysis Flag ASEVN Analysis Severity/Intensity (N) AOCCIFL 1st Max Sev./Int. Occurrence Flag AETOXGR Standard Toxicity Grade AETOXGRN Standard Toxicity Grade (N) AEACN_DECODE Action Taken Study Treatment DOSEDY Day Study Drug DOSEU Treatment Dose Units DOSEON Treatment Dose Record Start AECONTRT Concomitant Additional Trtmnt Given CQ01NAM Customized Query 01 Name CQ02NAM Customized Query 02 Name CQ03NAM Customized Query 03 Name AESMIE Medically Important Serious Event AESER_DECODE Serious Event AEREL_DECODE Causality AEOUT_DECODE Outcome Adverse Event AOCCFL 1st Occurence within Subject Flag AOCCPFL 1st Occurence within Preferred Term Flag AOCCSFL 1st Occurrence SOC Flag TRT01A Actual Treatment Period 01 SAFFL Safety Population Flag AGE Age SEX Sex RACE Race RACE_DECODE Race STUDYID Study Identifier AGEGR1 Pooled Age Group 1 TRTEDY Treatment Relative End Day TRT01P Planned Treatment Period 01 ACAT1 Analysis Category 1 FMQNAM FMQNAM FMQSOC FMQSOC FMQCLASS FMQCLASS","code":""},{"path":"/reference/adaefmq.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"adaefmq — adaefmq","text":"data adae pharmaverseadam , FDA_FMW_Consolidated_List.rds FDA_FMQ_References.rds","code":""},{"path":[]},{"path":"/reference/adaefmq.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"adaefmq — adaefmq","text":"","code":"if (FALSE) { # \\dontrun{ data(\"adaefmq\") } # }"},{"path":"/reference/adcm.html","id":null,"dir":"Reference","previous_headings":"","what":"adcm — adcm","title":"adcm — adcm","text":"adcm modified pharmaverseadam","code":""},{"path":"/reference/adcm.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"adcm — adcm","text":"","code":"adcm"},{"path":"/reference/adcm.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"adcm — adcm","text":"data frame 7276 rows 63 variables: DOMAIN Domain Abbreviation USUBJID Unique Subject Identifier CMSEQ Sequence Number CMSPID Sponsor-Defined Identifier CMTRT Reported Name Drug, Med, Therapy CMDECOD Standardized Medication Name CMINDC Indication CMCLAS Medication Class CMDOSE Dose per Administration CMDOSU Dose Units CMDOSFRQ Dosing Frequency per Interval CMROUTE Route Administration VISITNUM Visit Number VISIT Visit Name VISITDY Planned Study Day Visit CMDTC Date/Time Collection CMSTDTC Start Date/Time Medication CMENDTC End Date/Time Medication CMSTDY Study Day Start Medication CMENDY Study Day End Medication CMENRTPT End Relative Reference Time Point ASTDTM Analysis Start Date/Time ASTDTF Analysis Start Date Imputation Flag ASTTMF Analysis Start Time Imputation Flag AENDTM Analysis End Date/Time AENDTF Analysis End Date Imputation Flag AENTMF Analysis End Time Imputation Flag ASTDT Analysis Start Date AENDT Analysis End Date ASTDY Analysis Start Relative Day AENDY Analysis End Relative Day ADURN Analysis Duration (N) ADURU Analysis Duration Units ONTRTFL Treatment Record Flag PREFL Pre-treatment Flag FUPFL Follow-Flag ANL01FL Analysis Flag 01 AOCCPFL 1st Occurrence Preferred Term Flag APHASE Phase APHASEN Description Phase N TRTP Planned Treatment TRTA Actual Treatment CMLVL1 Preferred ATC Text ATC Level 1 CMLVL2 Preferred ATC Text ATC Level 2 CMLVL3 Preferred ATC Text ATC Level 3 CMLVL4 Preferred ATC Text ATC Level 4 CMBASPRF Base Preferred Term CMPRESP CM Pre-specified CMOCCUR CM Occurrence CMINDCSP Indication Specification CMDOSTXT Dose Description CMENRF End Relative Reference Period CQ01NAM Customized Query 01 Name CQ02NAM Customized Query 02 Name CQ03NAM Customized Query 03 Name CQ04NAM Customized Query 04 Name CQ05NAM Customized Query 05 Name CQ06NAM Customized Query 06 Name CQ07NAM Customized Query 07 Name TRT01A Actual Treatment Period 01 SAFFL Safety Population Flag TRTSDT Date First Exposure Treatment STUDYID Study Identifier","code":""},{"path":"/reference/adcm.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"adcm — adcm","text":"data pharmaverseadam.","code":""},{"path":[]},{"path":"/reference/adcm.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"adcm — adcm","text":"","code":"if (FALSE) { # \\dontrun{ data(\"adcm\") } # }"},{"path":"/reference/adeg.html","id":null,"dir":"Reference","previous_headings":"","what":"adeg — adeg","title":"adeg — adeg","text":"adeg modified pharmaverseadam","code":""},{"path":"/reference/adeg.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"adeg — adeg","text":"","code":"adeg"},{"path":"/reference/adeg.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"adeg — adeg","text":"data frame 13536 rows 71 variables: DOMAIN Domain Abbreviation USUBJID Unique Subject Identifier EGSEQ Sequence Number EGTESTCD ECG Test Examination Short Name EGTEST ECG Test Examination Name EGORRES Result Finding Original Units EGORRESU Original Units EGSTRESC Character Result/Finding Std Format EGSTRESN Numeric Result/Finding Standard Units EGSTRESU Standard Units EGSTAT Completion Status EGLOC Lead Location Used Measurement EGBLFL Baseline Flag VISITNUM Visit Number VISIT Visit Name VISITDY Planned Study Day Visit EGDTC Date/Time ECG EGDY Study Day ECG EGTPT Planned Time Point Name EGTPTNUM Planned Time Point Number EGELTM Planned Elapsed Time Time Point Ref EGTPTREF Time Point Reference ADTM Analysis Datetime ATMF Analysis Time Imputation Flag ADY Analysis Relative Day PARAMCD Parameter Code AVAL Analysis Value AVALC Analysis Value (C) ADT Analysis Date ATPTN Analysis Timepoint (N) ATPT Analysis Timepoint AVISIT Analysis Visit AVISITN Analysis Visit (N) DTYPE Derivation Type ONTRTFL Treatment Record Flag ANRLO Analysis Normal Range Lower Limit ANRHI Analysis Normal Range Upper Limit ANRIND Analysis Reference Range Indicator BASETYPE Baseline Type ABLFL Baseline Record Flag BASEC Baseline Value (C) CHG Change Baseline PCHG Percent Change Baseline ANL01FL Analysis Flag 01-Analysis Value TRTP Planned Treatment TRTA Actual Treatment ASEQ Analysis Sequence Number AVALCAT1 Analysis Value Category 1 AVALCA1N Analysis Value Category 1 (N) CHGCAT1 Change Baseline Category 1 CHGCAT1N Change Baseline Category 1 (N) PARAM Parameter PARAMN Parameter (N) TRTEMFL Treatment Emergent Analysis Flag ANL02FL Analysis Flag 02-Visit Value ANL03FL Analysis Flag 03-Maximum Value APOBLFL Post-Baseline Record Flag CRIT1 Analysis Criterion 1 CRIT1FL Criterion 1 Evaluation Result Flag CRIT2 Analysis Criterion 2 CRIT2FL Criterion 2 Evaluation Result Flag EGCLSIG ECG Clinical Significance BASE Baseline Value BNRIND Baseline Reference Range Indicator BASECAT1 Baseline Category 1 TRT01A Actual Treatment Period 01 SAFFL Safety Population Flag STUDYID Study Identifier AGE Age SEX Sex RACE_DECODE Race","code":""},{"path":"/reference/adeg.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"adeg — adeg","text":"data pharmaverseadam.","code":""},{"path":[]},{"path":"/reference/adeg.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"adeg — adeg","text":"","code":"if (FALSE) { # \\dontrun{ data(\"adeg\") } # }"},{"path":"/reference/adex.html","id":null,"dir":"Reference","previous_headings":"","what":"adex — adex","title":"adex — adex","text":"adex modified pharmaverseadam","code":""},{"path":"/reference/adex.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"adex — adex","text":"","code":"adex"},{"path":"/reference/adex.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"adex — adex","text":"data frame 591 rows 128 variables: STUDYID Study Identifier DOMAIN Domain Abbreviation USUBJID Unique Subject Identifier EXSEQ Sequence Number EXTRT Planned Treatment EXDOSE Adjusted Dose EXDOSU Dose Units EXDOSFRM Dose Form EXDOSFRQ Dosing Frequency per Interval EXROUTE Route Administration VISITNUM Visit Number VISIT Visit Name VISITDY Planned Study Day Visit EXSTDTC Start Date/Time Treatment EXENDTC End Date/Time Treatment EXSTDY Study Day Start Treatment EXENDY Study Day End Treatment EXADJ Reason Dose Adjustment EXPLDOS Planned Dose TRTSDT Date First Exposure Treatment TRTSDTM Datetime First Exposure Treatment TRTEDTM Datetime Last Exposure Treatment ASTDTM Analysis Start Datetime ASTDTF Analysis Start Date Imputation Flag ASTTMF Analysis Start Time Imputation Flag AENDTM Analysis End Datetime AENDTF Analysis End Date Imputation Flag AENTMF Analysis End Time Imputation Flag ASTDY Analysis Start Relative Day AENDY Analysis End Relative Day EXDURD Duration Treatment (Days) ASTDT Analysis Start Date AENDT Analysis End Date DOSEO Dose O PDOSEO PDose O PARAMCD Parameter Code AVAL Analysis Value AVALC Analysis Value (C) PARCAT1 Parameter Category 1 PARAM Parameter PARAMN Parameter (N) AVALCAT1 Analysis Value Category 1 ASEQ Analysis Sequence Number SUBJID Subject Identifier Study RFSTDTC Subject Reference Start Date/Time RFENDTC Subject Reference End Date/Time RFXSTDTC Date/Time First Study Treatment RFXENDTC Date/Time Last Study Treatment RFICDTC Date/Time Informed Consent RFPENDTC Date/Time End Participation DTHDTC Date/Time Death DTHFL Subject Death Flag SITEID Study Site Identifier AGE Age AGEU Age Units SEX Sex RACE Race ETHNIC Ethnicity ARMCD Treatment Category Code ARM Treatment Group ACTARMCD Actual Arm Code ACTARM Actual Treatment Group COUNTRY Country DMDTC Date/Time Collection DMDY Study Day Collection TRT01P Planned Treatment Period 01 TRT01A Actual Treatment Period 01 TRTSTMF Time First Exposure Imput. Flag TRTETMF Time Last Exposure Imput. Flag TRTEDT Date Last Exposure Treatment TRTDURD Total Treatment Duration (Days) SCRFDT Screen Failure Date EOSDT End Study Date EOSSTT End Study Status FRVDT Final Retrievel Visit Date RANDDT Date Randomization DTHDT Date Death DTHDTF Date Death Imputation Flag DTHADY Relative Day Death LDDTHELD Elapsed Days Last Dose Death DTHCAUS Cause Death DTHDOM Domain Date Death Collection DTHCGR1 Cause Death Reason 1 LSTALVDT Date Last Known Alive SAFFL Safety Population Flag RACEGR1 Pooled Race Group 1 AGEGR1 Age Group REGION1 Geographic Region 1 LDDTHGR1 Last Dose Death - Days Elapsed Grp 1 DTH30FL Death Within 30 Days Last Trt Flag DTHA30FL Death 30 Days Last Trt Flag DTHB30FL Death Within 30 Days First Trt Flag ATRT Analysis name Treatment DAEXPDTC Date Exposure EXLOT Lot Number ADOSE Analysis Dose TRT01PN Planned Treatment Period 01 (N) AVISITN Visit Number AVISIT Visit Label TRT01AN Actual Treatment Period 01 (N) AOCCUR Analysis Occurrence RACE_DECODE Race ACAT1 Analysis Category 1 AREASOC Analysis Reason Occur Value AREASOO Analysis Reason Occur Value AADJ Analysis Reason Dose Adjustment AADJPOTH Anal Reason Dose Adjust Prior AADJP Analysis Reason Dose Adjustment Prior AACTDU Analysis Action Taken Study Trt AACTDU1 Act Takn Dur Infus-Full Dose Admined AACTDU2 Act Takn Dur Infus-Infusion Aborted AACTDU3 Act Takn Dur Infus-Infusion Interrupted AACTDU4 Act Takn Dur Infus-Infusion Rate Decrsed AACTDU5 Act Takn Dur Infus-Infusion Rate Incrsed AADJOTH Anal Reason Dose Adjustment ACAT2 Analysis Category 2 AACTPR Action Taken Prior Infusion Start AACTPR_DECODE Action Taken Prior Infusion Start ASCHDOSE Analysis Scheduled Dose ASCHDOSU Analysis Scheduled Dose Units ADOSFRM Analysis Dose Form ADOSU Analysis Dose Units ADOSFRQ Analysis Dosing Frequency per Interval AROUTE Analysis Route Administration ATVINF Analysis Total Volume Infused ATVINFU Analysis Total Volume Infused Units AINFRAT Analysis Infusion Rate AINFRAU Analysis Infusion Rate Unit","code":""},{"path":"/reference/adex.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"adex — adex","text":"data pharmaverseadam.","code":""},{"path":[]},{"path":"/reference/adex.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"adex — adex","text":"","code":"if (FALSE) { # \\dontrun{ data(\"adex\") } # }"},{"path":"/reference/adexsum.html","id":null,"dir":"Reference","previous_headings":"","what":"adexsum — adexsum","title":"adexsum — adexsum","text":"adex modified pharmaverseadam","code":""},{"path":"/reference/adexsum.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"adexsum — adexsum","text":"","code":"adexsum"},{"path":"/reference/adexsum.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"adexsum — adexsum","text":"data frame 2794 rows 25 variables: USUBJID Unique Subject Identifier PARAMCD Parameter Code PARAM Parameter AVAL Analysis Value AVALCAT1 Analysis Value Category 1 AVALCA1N Analysis Value Category 1 (N) CRIT1 Analysis Criterion 1 CRIT1FL Criterion 1 Evaluation Result Flag CRIT2 Analysis Criterion 2 CRIT2FL Criterion 2 Evaluation Result Flag CRIT3 Analysis Criterion 3 CRIT3FL Criterion 3 Evaluation Result Flag CRIT4 Analysis Criterion 4 CRIT4FL Criterion 4 Evaluation Result Flag CRIT5 Analysis Criterion 5 CRIT5FL Criterion 5 Evaluation Result Flag CRIT6 Analysis Criterion 6 CRIT6FL Criterion 6 Evaluation Result Flag CRIT7 Analysis Criterion 7 CRIT7FL Criterion 7 Evaluation Result Flag AVISIT Analysis Visit AVISITN Analysis Visit (N) TRT01A Actual Treatment Period 01 SAFFL Safety Population Flag STUDYID Study Identifier","code":""},{"path":"/reference/adexsum.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"adexsum — adexsum","text":"data adex pharmaverseadam","code":""},{"path":[]},{"path":"/reference/adexsum.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"adexsum — adexsum","text":"","code":"if (FALSE) { # \\dontrun{ data(\"adexsum\") } # }"},{"path":"/reference/adlb.html","id":null,"dir":"Reference","previous_headings":"","what":"adlb — adlb","title":"adlb — adlb","text":"adlb modified pharmaverseadam","code":""},{"path":"/reference/adlb.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"adlb — adlb","text":"","code":"adlb"},{"path":"/reference/adlb.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"adlb — adlb","text":"data frame 83652 rows 152 variables: STUDYID Study Identifier DOMAIN Domain Abbreviation USUBJID Unique Subject Identifier LBSEQ Sequence Number LBTESTCD Lab Test Examination Short Name LBTEST Lab Test Examination Name LBCAT Category Lab Test LBORRES Result Finding Original Units LBORRESU Original Units LBORNRLO Reference Range Lower Limit Orig Unit LBORNRHI Reference Range Upper Limit Orig Unit LBSTRESC Character Result/Finding Std Format LBSTRESN Numeric Result/Finding Standard Units LBSTRESU Standard Units LBSTNRLO Reference Range Lower Limit-Std Units LBSTNRHI Reference Range Upper Limit-Std Units LBNRIND Reference Range Indicator LBBLFL Baseline Flag VISITNUM Visit Number VISIT Visit Name VISITDY Planned Study Day Visit LBDTC Date/Time Specimen Collection LBDY Study Day Specimen Collection TRTSDT Date First Exposure Treatment TRTEDT Date Last Exposure Treatment TRT01A Actual Treatment Period 01 TRT01P Planned Treatment Period 01 ADT Analysis Date ADY Analysis Relative Day PARAMCD Parameter Code PARAM Parameter PARAMN Parameter (N) PARCAT1 Parameter Category 1 AVAL Analysis Value AVALC Analysis Value (C) ANRLO Analysis Normal Range Lower Limit ANRHI Analysis Normal Range Upper Limit DTYPE Derivation Type AVISIT Analysis Visit AVISITN Analysis Visit (N) ONTRTFL Treatment Record Flag ANRIND Analysis Reference Range Indicator BASETYPE Baseline Type ABLFL Baseline Record Flag BASE Baseline Value BASEC Baseline Value (C) BNRIND Baseline Reference Range Indicator CHG Change Baseline PCHG Percent Change Baseline ATOXDSCL Analysis Toxicity Description Low ATOXDSCH Analysis Toxicity Description High ATOXGRL Analysis Toxicity Grade Low ATOXGRH Analysis Toxicity Grade High ATOXGR Analysis Toxicity Grade BTOXGRL Baseline Toxicity Grade Low BTOXGRH Baseline Toxicity Grade High BTOXGR Baseline Toxicity Grade R2BASE Ratio Baseline R2ANRLO Ratio Analysis Val compared ANRLO R2ANRHI Ratio Analysis Val compared ANRHI SHIFT1 Shift Baseline Analysis Value SHIFT2 Shift Baseline Overall Grade ANL01FL Analysis Flag 01 LVOTFL Last Value Treatment Record Flag TRTP Planned Treatment TRTA Actual Treatment ASEQ Analysis Sequence Number SUBJID Subject Identifier Study RFSTDTC Subject Reference Start Date/Time RFENDTC Subject Reference End Date/Time RFXSTDTC Date/Time First Study Treatment RFXENDTC Date/Time Last Study Treatment RFICDTC Date/Time Informed Consent RFPENDTC Date/Time End Participation DTHDTC Date/Time Death DTHFL Subject Death Flag SITEID Study Site Identifier AGE Age AGEU Age Units SEX Sex RACE Race ETHNIC Ethnicity ARMCD Planned Arm Code ARM Description Planned Arm ACTARMCD Actual Arm Code ACTARM Description Actual Arm COUNTRY Country DMDTC Date/Time Collection DMDY Study Day Collection TRTSDTM Datetime First Exposure Treatment TRTSTMF Time First Exposure Imput. Flag TRTEDTM Datetime Last Exposure Treatment TRTETMF Time Last Exposure Imput. Flag TRTDURD Total Treatment Duration (Days) SCRFDT Screen Failure Date EOSDT End Study Date EOSSTT End Study Status FRVDT Final Retrievel Visit Date RANDDT Date Randomization DTHDT Date Death DTHDTF Date Death Imputation Flag DTHADY Relative Day Death LDDTHELD Elapsed Days Last Dose Death DTHCAUS Cause Death DTHDOM Domain Date Death Collection DTHCGR1 Cause Death Reason 1 LSTALVDT Date Last Known Alive SAFFL Safety Population Flag RACEGR1 Pooled Race Group 1 REGION1 Geographic Region 1 LDDTHGR1 Last Dose Death - Days Elapsed Grp 1 DTH30FL Death Within 30 Days Last Trt Flag DTHA30FL Death 30 Days Last Trt Flag DTHB30FL Death Within 30 Days First Trt Flag TRT01PN Planned Treatment Period 01 (N) TRT01AN Actual Treatment Period 01 (N) AVALU Analysis Value - Units ANL02FL Analysis Record Flag 02-Analysis Value TRTEMFL Treatment Emergent Analysis Flag COUNTRY_DECODE Country RACE_DECODE Race Description ETHNIC_DECODE Ethnicity Description PARCAT2 Parameter Category 2 PARCAT3 Parameter Category 3 PARCAT4 Parameter Category 4 PARCAT5 Parameter Category 5 PARCAT6 Parameter Category 6 MCRIT2ML Multi-Response Criterion 2 Evaluation MCRIT1ML Multi-Response Criterion 1 Evaluation MCRIT1MN Multi-Response Criterion 1 Eval (N) MCRIT2MN Multi-Response Criterion 2 Eval (N) MCRIT1 Analysis Multi-Response Criterion 1 MCRIT2 Analysis Multi-Response Criterion 2 APOBLFL Post-Baseline Record Flag LBSTNRHQ Reference Limit Higher LBSTNRLQ Reference Limit Lower ATOXGRN Analysis Toxicity Grade (Numeric) ADTM Analysis Date/Time ATPT Analysis Timepoint TR01SDT Start Date Treatment Period 01 TR01EDT End Date Treatment Period 01 ANL03FL Analysis Record Flag 03 - Protocol Visit ANL04FL Analysis Flag 04 ANL05FL Analysis Flag 05 ANL06FL Analysis Flag 06 ANL07FL Analysis Flag 07 ANL08FL Analysis Flag 08 ANL09FL Analysis Flag 09 ANL10FL Analysis Flag 10 ANL14FL Analysis Flag 14 ANL15FL Analysis Flag 15 ANL16FL Analysis Flag 16","code":""},{"path":"/reference/adlb.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"adlb — adlb","text":"data pharmaverseadam.","code":""},{"path":[]},{"path":"/reference/adlb.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"adlb — adlb","text":"","code":"if (FALSE) { # \\dontrun{ data(\"adlb\") } # }"},{"path":"/reference/adsl.html","id":null,"dir":"Reference","previous_headings":"","what":"adsl — adsl","title":"adsl — adsl","text":"adsl modified pharmaverseadam","code":""},{"path":"/reference/adsl.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"adsl — adsl","text":"","code":"adsl"},{"path":"/reference/adsl.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"adsl — adsl","text":"data frame 306 rows 106 variables: STUDYID Study Identifier USUBJID Unique Subject Identifier SUBJID Subject Identifier Study RFSTDTC Subject Reference Start Date/Time RFENDTC Subject Reference End Date/Time RFXSTDTC Date/Time First Study Treatment RFXENDTC Date/Time Last Study Treatment RFICDTC Date/Time Informed Consent RFPENDTC Date/Time End Participation DTHDTC Date/Time Death DTHFL Subject Death Flag SITEID Study Site Identifier AGE Age AGEU Age Units SEX Sex RACE Race ETHNIC Ethnicity ARMCD Planned Arm Code ARM Description Planned Arm ACTARMCD Actual Arm Code ACTARM Description Actual Arm COUNTRY Country DMDTC Date/Time Collection DMDY Study Day Collection TRT01P Planned Treatment Period 01 TRT01A Actual Treatment Period 01 TRTSDTM Datetime First Exposure Treatment TRTSTMF Time First Exposure Imput. Flag TRTEDTM Datetime Last Exposure Treatment TRTETMF Time Last Exposure Imput. Flag TRTSDT Date First Exposure Treatment TRTEDT Date Last Exposure Treatment TRTDURD Total Treatment Duration (Days) SCRFDT Screen Failure Date EOSDT End Study Date EOSSTT End Study Status FRVDT Final Retrievel Visit Date RANDDT Date Randomization DTHDT Date Death DTHDTF Date Death Imputation Flag DTHADY Relative Day Death LDDTHELD Elapsed Days Last Dose Death DTHCAUS Cause Death DTHDOM Domain Date Death Collection DTHCGR1 Cause Death Reason 1 LSTALVDT Date Last Known Alive SAFFL Safety Population Flag RACEGR1 Pooled Race Group 1 AGEGR1 Pooled Age Group 1 REGION1 Geographic Region 1 LDDTHGR1 Last Dose Death - Days Elapsed Grp 1 DTH30FL Death Within 30 Days Last Trt Flag DTHA30FL Death 30 Days Last Trt Flag DTHB30FL Death Within 30 Days First Trt Flag TRT01PN Planned Treatment Period 01 (N) TRT01AN Actual Treatment Period 01 (N) AGEGR1N Pooled Age Group 1 (N) SEX_DECODE Sex WEIGHTBL Weight (kg) WGTGR1N Weight Group 1 (N) WGTGR1 Weight Group 1 HEIGHTBL Height (cm) BSABL Body surface area (m2) BMIBL Body mass index (kg/m2) BMIBLG1N BMI Baseline Group 1 (N) BMIBLG1 BMI Baseline Group 1 COUNTRY_DECODE Country RACE_DECODE Race RFICDT Date Informed Consent ETHNIC_DECODE Ethnicity STRAT1R Strat Factor 1 Value Used Rand STRAT2R Strat Factor 2 Value Used Rand RANUM Randomization Number RANDDTM Datetime Randomization EOTSTT End Treatment Status DCTREAS Reason Discontinuation Treatment LTVISIT Last Treatment Visit DCTREASP Reason Specify Discont Treatment DCTDT End Study Date DCSREAS Reason Discontinuation Study DCSREASP Reason Spec Discont Study LSVISIT Last Study Visit TRTEDY Treatment Relative End Day SCRNFL Screened Population Flag SCRFFL Screen Failure Flag DCSCREEN Reason Discont Screening ENRLFL Enrolled Population Flag RANDFL Randomized Flag ITTFL Intent--Treat Population Flag FASFL Full Analysis Set Population Flag PPROTFL Per-Protocol Population Flag LSTSVDT Last Subject Visit (SV) Date EOSDY Study Day Study Termination UNBLNDFL Subject Blind Broken RESCRNFL Re-screened Flag DTHTRTFL Death Treatment Flag DTHCAUSP Cause Spec Death DTHAFTFL Death 30 Days Last Treatment DTH60TFL Death Within 60 Days First Treatment UNBLNDDY Study Day Unblinding UNBREAS Reason Unblinding LDOSE Last Dose LDOSU Last Dose Unit DTHTERM Reported Cause Death LDSTODTH Days Last Dose Death DTHDY Study Day Death","code":""},{"path":"/reference/adsl.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"adsl — adsl","text":"data pharmaverseadam.","code":""},{"path":[]},{"path":"/reference/adsl.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"adsl — adsl","text":"","code":"if (FALSE) { # \\dontrun{ data(\"adsl\") } # }"},{"path":"/reference/adttesaf.html","id":null,"dir":"Reference","previous_headings":"","what":"adttesaf — adttesaf","title":"adttesaf — adttesaf","text":"adtte_onc modified pharmaverseadam","code":""},{"path":"/reference/adttesaf.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"adttesaf — adttesaf","text":"","code":"adttesaf"},{"path":"/reference/adttesaf.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"adttesaf — adttesaf","text":"data frame 2032 rows 9 variables: USUBJID Unique Subject Identifier PARAMCD Parameter Code PARAM Parameter AVAL Analysis Value CNSR Censor STARTDT Start Date ADT Analysis Date TRT01A Actual Treatment Period 01 SAFFL Safety Population Flag","code":""},{"path":"/reference/adttesaf.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"adttesaf — adttesaf","text":"data adtte_onc pharmaverseadam","code":""},{"path":[]},{"path":"/reference/adttesaf.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"adttesaf — adttesaf","text":"","code":"if (FALSE) { # \\dontrun{ data(\"adttesaf\") } # }"},{"path":"/reference/advs.html","id":null,"dir":"Reference","previous_headings":"","what":"advs — advs","title":"advs — advs","text":"advs modified pharmaverseadam","code":""},{"path":"/reference/advs.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"advs — advs","text":"","code":"advs"},{"path":"/reference/advs.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"advs — advs","text":"data frame 40702 rows 78 variables: DOMAIN Domain Abbreviation USUBJID Unique Subject Identifier VSSEQ Sequence Number VSTESTCD Vital Signs Test Short Name VSTEST Vital Signs Test Name VSPOS Vital Signs Position Subject VSORRES Result Finding Original Units VSORRESU Original Units VSSTRESC Character Result/Finding Std Format VSSTRESN Numeric Result/Finding Standard Units VSSTRESU Standard Units VSSTAT Completion Status VSLOC Location Vital Signs Measurement VSBLFL Baseline Flag VISITNUM Visit Number VISIT Visit Name VISITDY Planned Study Day Visit VSDTC Date/Time Measurements VSDY Study Day Vital Signs VSTPT Planned Time Point Name VSTPTNUM Planned Time Point Number VSELTM Planned Elapsed Time Time Point Ref VSTPTREF Time Point Reference ADT Analysis Date ADY Analysis Relative Day PARAMCD Parameter Code AVAL Analysis Value ATPTN Analysis Timepoint (N) ATPT Analysis Time Point AVISIT Analysis Visit AVISITN Analysis Visit (N) DTYPE Derivation Type ONTRTFL Treatment Record Flag ANRLO Analysis Normal Range Lower Limit ANRHI Analysis Normal Range Upper Limit A1LO Analysis Range 1 Lower Limit A1HI Analysis Range 1 Upper Limit ANRIND Analysis Reference Range Indicator BASETYPE Baseline Type ABLFL Baseline Record Flag CHG Change Baseline PCHG Percent Change Baseline ANL01FL Analysis Flag 01 TRTP Planned Treatment TRTA Actual Treatment ASEQ Analysis Sequence Number AVALCAT1 Analysis Value Category 1 AVALCA1N Analysis Value Category 1 (N) PARAM Parameter PARAMN Parameter (N) AVALC Analysis Value (C) ANL02FL Analysis Flag 02-Visit Value APOBLFL Post-Baseline Record Flag BASE Baseline Value BNRIND Baseline Reference Range Indicator ADTM Analysis Date/Time CRIT1 Analysis Criterion 1 CRIT1FL Criterion 1 Evaluation Result Flag CRIT2 Analysis Criterion 2 CRIT2FL Criterion 2 Evaluation Result Flag CRIT3 Analysis Criterion 3 CRIT3FL Criterion 3 Evaluation Result Flag ATOXDSCL Analysis Toxicity Description Low ATOXDSCH Analysis Toxicity Description High ATOXGRL Analysis Toxicity Grade Low ATOXGRH Analysis Toxicity Grade High ATOXGR Analysis Toxicity Grade ANL06FL Analysis Flag 06-Minimum Value ANL05FL Analysis Flag 05-Worst Tox Grade High ANL04FL Analysis Flag 04-Worst Value ANL03FL Analysis Flag 03-Maximum Value TRTEMFL Treatment Emergent Analysis Flag TRT01A Actual Treatment Period 01 SAFFL Safety Population Flag STUDYID Study Identifier AGE Age SEX Sex RACE_DECODE Race","code":""},{"path":"/reference/advs.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"advs — advs","text":"data pharmaverseadam.","code":""},{"path":[]},{"path":"/reference/advs.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"advs — advs","text":"","code":"if (FALSE) { # \\dontrun{ data(\"advs\") } # }"},{"path":"/reference/pharmaverseadamjnj-package.html","id":null,"dir":"Reference","previous_headings":"","what":"pharmaverseadamjnj: J&J Innovative Medicine ADaM Test Data — pharmaverseadamjnj-package","title":"pharmaverseadamjnj: J&J Innovative Medicine ADaM Test Data — pharmaverseadamjnj-package","text":"set Analysis Data Model (ADaM) datasets constructed modifying ADaM datasets 'pharmaverseadam' package meet J&J Innovative Medicine's standard data structure Clinical Statistical Programming.","code":""},{"path":"/reference/pharmaverseadamjnj-package.html","id":"author","dir":"Reference","previous_headings":"","what":"Author","title":"pharmaverseadamjnj: J&J Innovative Medicine ADaM Test Data — pharmaverseadamjnj-package","text":"Maintainer: David Munoz Tord david.munoztord@mailbox.org Authors: Nicholas Masel nmasel@.jnj.com Joe Kovach jkovach2@.jnj.com contributors: Mahesh Divakaran mdivaka2@.jnj.com [contributor] J&J Innovative Medicine [copyright holder, funder]","code":""},{"path":[]},{"path":"/news/index.html","id":"initial-cran-release-0-0-1","dir":"Changelog","previous_headings":"","what":"Initial CRAN release","title":"pharmaverseadamjnj 0.0.1","text":"First release pharmaverseadamjnj package Provides ADaM datasets comply J&J Innovative Medicine standards Built top pharmaverseadam package Implements data conversion pharmaverse format J&J standards format Provides reproducible consistent test data","code":""},{"path":"/news/index.html","id":"implemented-adam-domains-0-0-1","dir":"Changelog","previous_headings":"Initial CRAN release","what":"Implemented ADaM Domains","title":"pharmaverseadamjnj 0.0.1","text":"ADSL (Subject Level Analysis Dataset) ADAE (Adverse Events Analysis Dataset) ADCM (Concomitant Medications Analysis Dataset) ADEG (ECG Analysis Dataset) ADEX (Exposure Analysis Dataset) ADESUM (Exposure Analysis Summary Dataset) ADLB (Laboratory Test Results Analysis Dataset) ADVS (Vital Signs Analysis Dataset) ADTTESAF (Time--Event Safety Analysis Dataset) ADAEFMQ (Adverse Events Analysis Dataset FDA Medical Query)","code":""}]
